Insider Buying: NGM Biopharmaceuticals (NYSE:NGM) Major Shareholder Purchases 25,200 Shares of Stock

NGM Biopharmaceuticals (NYSE:NGM) major shareholder Group L. P. Column bought 25,200 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were bought at an average cost of $13.40 per share, for a total transaction of $337,680.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NYSE:NGM opened at $14.64 on Friday. NGM Biopharmaceuticals has a 1-year low of $12.00 and a 1-year high of $18.75. The company’s fifty day simple moving average is $14.03.

NGM Biopharmaceuticals (NYSE:NGM) last issued its earnings results on Thursday, May 16th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.90). The business had revenue of $25.55 million during the quarter.

A number of equities research analysts have recently issued reports on NGM shares. Cowen assumed coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set an “outperform” rating and a $25.00 target price on the stock. Goldman Sachs Group assumed coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set a “buy” rating and a $22.00 price target on the stock. Citigroup assumed coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set a “buy” rating and a $29.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on NGM Biopharmaceuticals in a research report on Monday, June 24th. They set a “buy” rating and a $26.00 price target on the stock.

About NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.

See Also: Why is the price target of stocks important?

Insider Buying and Selling by Quarter for NGM Biopharmaceuticals (NYSE:NGM)

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.